FTC Gives Green Light To ANI-Novitium Acquisition Conditions

Follows Public Comment Period; ANI Announced Completion In November

ANI is now firmly in the clear for its $210m acquisition of Novitium, following FTC approval of an order requiring divestiture of rights and assets to two generic products. The US-based firm is on an upward trajectory following its recent approval for Cortrophin Gel.

Green traffic light
Analysts praised ANI for having "real top line momentum" • Source: Alamy

The US Federal Trade Commission has voted 4-0 approving a final order to settle charges that ANI Pharmaceuticals’ $210m acquisition of Novitium Pharma violated federal antitrust laws, following a public comment period.

In November last year, the FTC told ANI it must divest development rights for one generic drug and assets belonging to another to authorized generics specialist Prasco, in order to close

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business